India: Recent Orders Of CCI Against Anti-Competitive Practices In The Pharmaceutical Industry

Last Updated: 17 June 2014
Article by Mrinali Mudoi

Most Read Contributor in India, September 2016

The Indian pharmaceutical industry is emerging as one of the most prospective markets in the global strata in terms of its potential and factors such as lower labor cost, resource availability etc. which is bringing it to the limelight of various international giant players all across the globe for venturing into business or investments in the Indian domestic market. However, the growth emergence of the market is also leading to the emergence of certain practices in the market affecting the pace of growth of the market which may in certain point, led to a descending dive as it discourages the enthusiasm of those international giants to venture into the complicacies of the Indian market.

Recently, the industry has witnessed of practices by the players of the market, which acts as disrupting factors against "the positive competition" in the market which is an essential ingredient of every market so as it to proceed towards more innovations and developments as an outcome of such positive competition.

In the study on "Option for using Competition Law/ policy tools in dealing with anti-competitive practices in the Pharmaceuticals Industry in the Health delivery System" prepared for WHO and the Ministry of Health and Family Welfare in 20061, it is quoted that anticompetitive practices in the pharmaceuticals sector and the health delivery system in India, includes, amongst others, price fixing, abuse of dominance, collusive agreements and tied selling.

In India, the Competition Commission of India ('CCI') is the authority which has established under the Competition Act, 2002 (Act) to eliminate practices having adverse effect on competition, promote and sustain competition, protect the interests of consumers and ensure freedom of trade carried on by other participants, in markets in India. It covers within its ambit all categories of 'markets' in India including the pharmaceuticals sector as well. Moreover, the Act is extra-territorial and assumes jurisdiction over acts even outside India that may affect a market within India.

This article endeavors to throw light on the recent regulatory steps of CCI towards prevention of anticompetitive practices in the pharmaceutical industry and discusses some of its recent orders to regulate anti-competitive practices in the pharmaceutical market.

Implementation of the regulatory mechanism by the CCI

In a recent judgment Bengal Chemist and Druggist Association,2the CCI Imposes penalty of Rs. 18.38 crores on Bengal Chemist and Druggist Association (BCDA).3

Facts: BCDA, an association of wholesalers and retail sellers of drugs and affiliated to All India Organization of Chemist and Druggist was engaged in directly or indirectly determining the sale price of drugs and controlling the supply of drugs in a concerted manner and in issuing anti-competitive circulars directing the retailers not to give any discount to the consumers. The CCI after considering the entire material directed the Director General (DG) to cause an investigation into the matter and to submit a report.4

Investigation report by Direct or General

The Director General, in light of the investigation conducted, opined that the BCDA directed the retailers to sell the drugs only at MRP determined by it on account of agreement entered into amongst the members of the BCDA and that no discounts be offered by the retailers, it clearly implies that, then such a trade practice causes or is likely to cause an appreciable adverse effect on competition, especially when almost all the retailers and wholesalers are members of BCDA. The DG concluded that the above said conduct has resulted or is likely to result in controlling and or limiting supply of medicines and the market of provision of drugs, which contravene the provisions of Section 3(3)(b) of the Act.

CCI's finding:

The CCI firstly, dealt with the question as to whether BCDA is covered under the category of 'entities' under Section 3(3) read with Section 2(h) of the Act and whether the alleged practices of BCDA falls under "practice carried on" or decision taken by "an association of enterprises" under Section 3(3) of the Act. The CCI concluded that BCDA, being an association of its constituent enterprises, is taking decisions relating to distribution and supply of pharma products on behalf of the members who are engaged in similar or identical trade of goods and that such practices carried on, or decisions taken, by BCDA as an association of enterprises are covered within the scope of Section 3(3) of the Act.

Further, the CCI holds that the attempt of BCDA to justify sale of drugs only on MRP on the basis that the margins have been fixed under the DPCO and accepted in the market is untenable as the issue is not the reasonability or the quantum of trade margins but the concerted action to fix uniform trade margin by an agreement amongst the members of the trade association. The CCI found the activities of the BCDA in conflict with the objects of the competition law as they cause restraint of trade, stifle competition and harm the consumers.


The CCI directed the BCDA and its office bearers & executive committee members to seize and desist from indulging in anticompetitive practices found to be anticompetitive in terms of the provisions of Section 3 of the Act. The BCDA has been further directed to file an undertaking within 30 days that the CCI's directions have been complied with. The amount of penalty imposed was directed to be deposited within 60 of the receipt of the order.

In another judgment, M/s Arora Medical Hall, Ferozepur v. Chemists &Druggists Association, Ferozepur (CDAF),5 the CCI ordered another judgment imposing a penalty of Rs.55.42 lakhs on Ferozepur Chemists and Druggists Association.6

Facts: M/s Arora Medical Hall, Ferozepur informed the CCI that the CDAF made a mandatory rule in 2010 that any chemist/ druggist who wishes to take distributorship for medicines of a company in Ferozepur city to get a NOC and Letter of Credit (LOC) from CDAF by making a payment of Rs. 2100/- per company. The informant alleged that when it objected to the said rule, it was expelled from the primary membership of CDAF and passed a resolution to boycott the informant directing its members to stop purchasing goods from the informant and directed all the wholesalers to stop dealings with the retailers who continued to purchase goods from the informant and thereby, alleged to have violated the provisions of sections 3 and 4 of the Competition Act.

The Director General reported that CDAF's practice of necessarily requiring NOC to be taken from it prior to appointment of a new/ additional stockist in Ferozepur and indulging in the practice of non-grant of NOC to non-members is foreclosing the market for such nonmember which has the effect of limiting and controlling the supply of drugs and medicines in Ferozepur.

Order of CCI

The CCI directed CDAF to cease and desist from indulging in such anti-competitive practices which have been found to be anti-competitive in terms of the provisions of section 3(3)(b) read with Section 3(1) of the Act and imposed penalty accordingly.

On 3 February 2014, Press Information Bureau, Government of India, Ministry of Corporate Affairs vide press release informed that CCI has found the following practices of All India level, State level, District level associations of chemists, druggists, stockists, wholesellers and manufacturers as anti-competitive:

  1. Issuance of No Objection Certificate or letter of consent by such associations for opening chemist shop/being appointed stockists/ distributor/whole-seller.
  2. Compulsory payment of PIS charges by pharmaceutical firms/manufacturers to associations for release of new drug/new formulation.
  3. Fixation of trade margins at different levels of sale of drugs/medicines.
  4. Issuance of instructions to chemists/ druggists/shops/stockists/whole-sellers/ manufacturers restricting discounts on sale of drugs in retail or wholesale.
  5. Issuance of boycott calls by the associations to their members against any enterprise for not following the instructions of associations.

It is also mentioned in the press release dated 3 February 2014 that penalties have been imposed by the CCI on such trade associations of chemists and druggists for violation of provisions of Competition Act. The CCI had issued cease & desist order against the associations directing them not to indulge in anticompetitive practices and the associations have filed undertakings that they would not indulge in such illegal practices.


It is noteworthy that the CCI's stringency towards the objective of eliminating and regulating against the malpractices from the pharmaceutical market is also evidently clear from the press release of 3 February 2014 that in case any drug manufacturer or concerned party is victim of any anti- competitive practice described above, it may notify the CCI who shall take appropriate action as required, usually in the nature of criminal proceedings against the guilty associations and its office-bearers, and imposition of heavy monetary penalty.

To conclude with, such initiatives by CCI clearly indicate that it intends to bring into its stringent control on the mechanism of the pharmaceutical industry so as to regulate it against all the anti-competitive practices prevailing in the market thereby deterring those players of the market who indulged into such practices for their gain.

It further expected to bring a positive impact on the distribution of medicines in India as well as prices charged to the customers, thus with it, the hope that the Indian pharmaceutical market will move towards being more systematic and organized.



2. Suo moto Case No. 02 of 2012 and Ref. Case No. 01 of 2013, Competition Commission of India order, available at http://

3. Press Information Bureau, Ministry of Corporate Affairs, Government of India notification available at newsite/PrintRelease.aspx?relid=104597.

4. This has been done vide a common order in Suo moto Case No. 02 of 2012 and Reference Case No. 01 of 2013 filed by Dr. Chintamoni Ghosh, Director, Directorate of Drugs, West Bengal.

5. Case No. 60 of 2012, Competition Commission of India order, available at .

6. Press Information Bureau, Ministry of Corporate Affairs, Government of India notification available at newsite/PrintRelease.aspx?relid=103171

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.